350 related articles for article (PubMed ID: 27439658)
1. Joint bleeds increase the inhibitor response to human factor VIII in a rat model of severe haemophilia A.
Lövgren KM; Søndergaard H; Skov S; Wiinberg B
Haemophilia; 2016 Sep; 22(5):772-9. PubMed ID: 27439658
[TBL] [Abstract][Full Text] [Related]
2. Inhibitor development in two cousins receiving full-length factor VIII (FVIII) and FVIII-Fc fusion protein.
Ragni MV; Alabek M; Malec LM
Haemophilia; 2016 Sep; 22(5):e462-4. PubMed ID: 27501368
[No Abstract] [Full Text] [Related]
3. Antibody response to recombinant human coagulation factor VIII in a new rat model of severe hemophilia A.
Lövgren KM; Søndergaard H; Skov S; Weldingh KN; Tranholm M; Wiinberg B
J Thromb Haemost; 2016 Apr; 14(4):747-56. PubMed ID: 26784374
[TBL] [Abstract][Full Text] [Related]
4. Recombinant factor VIII Fc fusion protein for the prevention and treatment of bleeding in children with severe hemophilia A.
Young G; Mahlangu J; Kulkarni R; Nolan B; Liesner R; Pasi J; Barnes C; Neelakantan S; Gambino G; Cristiano LM; Pierce GF; Allen G
J Thromb Haemost; 2015 Jun; 13(6):967-77. PubMed ID: 25912075
[TBL] [Abstract][Full Text] [Related]
5. Allergic reaction in a cohort of haemophilia A patients using plasma-derived factor VIII (FVIII) concentrate is rare and not necessarily triggered by FVIII.
Montalvão SA; Tucunduva AC; Siqueira LH; Sambo AL; Medina SS; Ozelo MC
Haemophilia; 2015 Jul; 21(4):e281-5. PubMed ID: 25929310
[TBL] [Abstract][Full Text] [Related]
6. Non-genetic risk factors in haemophilia A inhibitor management - the danger theory and the use of animal models.
Lövgren KM; Søndergaard H; Skov S; Wiinberg B
Haemophilia; 2016 Sep; 22(5):657-66. PubMed ID: 27562315
[TBL] [Abstract][Full Text] [Related]
7. Acute Haemarthrosis in the Haemophilia A Rat Generates a Local and Systemic Proinflammatory Response.
Lövgren KM; Christensen KR; Majewski W; Østrup O; Skov S; Wiinberg B
Thromb Haemost; 2017 Nov; 117(11):2092-2104. PubMed ID: 29202211
[No Abstract] [Full Text] [Related]
8. Prophylaxis vs. on-demand treatment with Nuwiq(®) (Human-cl rhFVIII) in adults with severe haemophilia A.
Tiede A; Oldenburg J; Lissitchkov T; Knaub S; Bichler J; Manco-Johnson MJ
Haemophilia; 2016 May; 22(3):374-80. PubMed ID: 26582282
[TBL] [Abstract][Full Text] [Related]
9. Diagnostic accuracy study of a factor VIII ELISA for detection of factor VIII antibodies in congenital and acquired haemophilia A.
Batty P; Moore GW; Platton S; Maloney JC; Palmer B; Bowles L; Pasi KJ; Rangarajan S; Hart DP
Thromb Haemost; 2015 Oct; 114(4):804-11. PubMed ID: 26063073
[TBL] [Abstract][Full Text] [Related]
10. Exploring the Potential Feasibility of Intra-Articular Adeno-Associated Virus-Mediated Gene Therapy for Hemophilia Arthropathy.
Zhang F; Yan X; Li M; Hua B; Xiao X; Monahan PE; Sun J
Hum Gene Ther; 2020 Apr; 31(7-8):448-458. PubMed ID: 32079420
[TBL] [Abstract][Full Text] [Related]
11. Inhibitor development in previously untreated patients with severe haemophilia A: a nationwide multicentre study in Finland.
Vepsäläinen K; Lassila R; Arola M; Huttunen P; Koskinen S; Ljung R; Lähteenmäki P; Möttönen M; Riikonen P
Haemophilia; 2016 Sep; 22(5):721-9. PubMed ID: 27339837
[TBL] [Abstract][Full Text] [Related]
12. Expanding the ortholog approach for hemophilia treatment complicated by factor VIII inhibitors.
Zakas PM; Vanijcharoenkarn K; Markovitz RC; Meeks SL; Doering CB
J Thromb Haemost; 2015 Jan; 13(1):72-81. PubMed ID: 25315236
[TBL] [Abstract][Full Text] [Related]
13. Long-term secondary prophylaxis with recombinant activated factor VII (rFVIIa) in haemophilia A with inhibitors: a case report.
Kubisz P; Plamenová I; Stasko J; Dobrotová M; Hollý P
Thromb Haemost; 2010 Apr; 103(4):868-70. PubMed ID: 20135075
[No Abstract] [Full Text] [Related]
14. Safety and efficacy of a glycoPEGylated rFVIII (turoctocog alpha pegol, N8-GP) in paediatric patients with severe haemophilia A.
Meunier S; Alamelu J; Ehrenforth S; Hanabusa H; Abdul Karim F; Kavakli K; Khodaie M; Staber J; Stasyshyn O; Yee DL; Rageliene L
Thromb Haemost; 2017 Aug; 117(9):1705-1713. PubMed ID: 28692108
[TBL] [Abstract][Full Text] [Related]
15. Factor VIII products and inhibitor development in previously treated patients with severe or moderately severe hemophilia A: a systematic review.
Hassan S; Cannavò A; Gouw SC; Rosendaal FR; van der Bom JG
J Thromb Haemost; 2018 Jun; 16(6):1055-1068. PubMed ID: 29665204
[TBL] [Abstract][Full Text] [Related]
16. Prospective surveillance study of haemophilia A patients switching from moroctocog alfa or other factor VIII products to moroctocog alfa albumin-free cell culture (AF-CC) in usual care settings.
Parra Lopez R; Nemes L; Jimenez-Yuste V; Rusen L; Cid AR; Charnigo RJ; Baumann JA; Smith L; Korth-Bradley JM; Rendo P
Thromb Haemost; 2015 Oct; 114(4):676-84. PubMed ID: 26293201
[TBL] [Abstract][Full Text] [Related]
17. Neutralizing capacity of inhibitors on FVIII is lower for natural FVIII/VWF complex than for isolated FVIII: in vitro comparative study in eleven different therapeutic FVIII concentrates.
Bravo MI; Ortiz AM; Costa M; Grancha S; Jorquera JI
Haemophilia; 2016 Jul; 22(4):e341-4. PubMed ID: 27354216
[No Abstract] [Full Text] [Related]
18. Acquired haemophilia: management of bleeds and immune therapy to eradicate autoantibodies.
Holme PA; Brosstad F; Tjønnfjord GE
Haemophilia; 2005 Sep; 11(5):510-5. PubMed ID: 16128896
[TBL] [Abstract][Full Text] [Related]
19. Bleed volume of experimental knee haemarthrosis correlates with the subsequent degree of haemophilic arthropathy.
Vøls KK; Kjelgaard-Hansen M; Ley CD; Hansen AK; Petersen M
Haemophilia; 2019 Mar; 25(2):324-333. PubMed ID: 30648774
[TBL] [Abstract][Full Text] [Related]
20. Some recent developments regarding arthropathy and inhibitors in haemophilia.
Rodriguez-Merchan EC
Haemophilia; 2008 Mar; 14(2):242-7. PubMed ID: 18201189
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
